ARRY-300

also known as MET-300

targets MET via inhibition

today NCT00828165 · Ph 1

2009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT00828165	Jan → Apr 2009	—	Array BioPharma	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	ARRY-300	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00828165 ↗
Known as	MET-300	ChEMBL registry synonym — accepted as the source's own label CHEMBL3545359 ↗
Action	Inhibit	“Hepatocyte growth factor receptor inhibitor” CHEMBL3545359 ↗ 1 “MEK inhibitor” NCT00828165 ↗
Route	Oral	“oral” NCT00828165 ↗
Target	MET	“Hepatocyte growth factor receptor inhibitor” CHEMBL3545359 ↗